Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

Second Orphan Drug Designation Supports Azafaros' Strategy to Develop AZ-3102 as a Disease Modifying Treatment in a Range of Severe Rare Inherited Metabolic Disorders Azafaros B.V. today announced

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Switzerland ,Dutch ,Swiss ,Kostenloser Wertpapierhandel ,Eva Mulder ,Marie Theresa Weickert ,Schroder Adveq ,Amsterdam University Medical Center ,Drug Administration ,Leiden University ,Trophic Communications ,Disease Modifying Treatment ,Severe Rare Inherited Metabolic Disorders ,Orphan Drug Designation ,Stefano Portolano ,Chief Executive Officer ,Drug Designation ,Amsterdam University Medical ,Biogeneration Ventures ,Azafaros ,Nnounces ,Rant ,Orphan ,Drug ,Resignation ,102 ,Treatment ,Niemann ,Kick ,Disease ,